Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
DOI 10.32782/2226-2008-2023-4-6
Introduction. The pandemic of metabolically associated fatty liver disease, that begins with metabolically associated hepatic steatosis (MAHS), affects the course of ischemic heart disease (IHD). According to the literature, MAHS is associated with increased calcification of coronary arteries already at the stage of steatosis, although the impact on the long-term prognosis of patients is not enough established.
The aim of the study – is to determine the impact of MAHS on the long-term prognosis of patients with chronic forms of IHD.
Materials and methods. For 3 years, 85 men in the age group 36-78 years old (median 57 years old) with ischemic heart disease, stable angina pectoris of I-III functional classes were observed. They were divided into two comparable groups: with MAHS (13%) and intact liver (87%). MAHS criteria: ultrasound signs of increased acoustic density of the liver compared to the kidneys, a moderate increase in the size of the liver; slight expansion of the splenic and portal veins, poor visualization of the central vessels; absence of the laboratory signs of mesenchymal inflammation activity and cytolysis (EASL-EASD-EASO Clinical Practice Guidelines for the Management of Non-alcoholic Fatty Liver Disease, 2016). Prognosis was assessed by Kaplan-Meier with determination of significance by the Cox test or Gehan-Wilcoxon test, the composite end point was an acute cardiovascular event.
Results. In patients with chronic forms of ischemic heart disease, the presence of metabolically associated steatosis of the liver is an independent predictor of the development of acute cardiovascular events within three years. Unfavorable predictors of 3-year survival in patients with chronic forms of IHD were also low cholesterol – high-density lipoproteins content (<1,0 mmol/l) and increased levels of triglycerides (≥1,7 mmol/l), total fibrinogen (> 4 g/l) and soluble fibrin monomer complexes (≥ 4 mg/dL).
Conclusion. Unfavorable prognostic factors for the long-term prognosis in patients with IHD were the presence of hepatic steatosis, lipid disorders, and hypercoagulation.
Key words: metabolic-associated steatosis of the liver, ischemic heart disease, prognosis, hypercoagulation, triglycerides.
REFERENCES
- Lin HXJ, Aravamudan Metabolic associated fatty liver disease and COVID-19: a double whammy? Singapore Medical 2020;PMID: 33047142. https://read.qxmd.com/read/33047142/metabolic-associated-fatty-liver-disease-and-covid-19-a- double-whammy
- Chang Y, Ryu S, Sung KC, et al. Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung Health Study 2019;68(9):1667-1675.doi:10.1136/gutjnl-2018-317666
- Kim SH, Park HY, Lee HS, Jung KS, Lee MH et al. Association between non-alcoholic fatty liver disease and coronary calcification depending on sex and obesity Sci Rep. 2020;10(1):1025. doi: 1038/s41598-020-57894-y
- Brouwers MCGJ, Simons N, Stehouwer CDA, Isaacs A. Non-alcoholic fatty liver disease and cardiovascular disease: assessing the evidence for causality 2020;63(2):253-260. doi: 10.1007/s00125-019-05024-3
- Liu Z, Wei R, Li Y., et al. Coronary heart disease is associated with nonalcoholic fatty liver disease in patients without hypertension and diabetes Medicine (Baltimore). 2020;99(26):e20898. doi: 1097/MD.0000000000020898
- Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysiJ Hepatol. 2016;65(3):589-600. doi: 10.1016/j.jhep.2016.05.013
- Pais R, Ratziu V. Reply to “Establishing the independence and clinical importance of non-alcoholic fatty liver disease as a risk factor for cardiovascular disease”J 2016;65(6):1267-1268. doi: 10.1016/j.jhep.2016.07.038
- Park J, Kim G, Kim H, et al. The association of hepatic steatosis and fibrosis with heart failure and mortality Cardiovasc Diabetol. 2021;20(1):197. doi: 10.1186/s12933-021-01374-8.